Gain hopes to prove Parkinson's drug's potential next year after phase 1 win for allosteric modulator

Gain Therapeutics has set its sights on proving the effectiveness of its Parkinson’s disease therapy next year after the brain-penetrant small molecule demonstrated “peripheral target engagement” in a phase 1 trial.